glimepiride + pioglitazone

**Glimepiride + pioglitazone** is a fixed-dose oral combination of two antihyperglycemic agents used to improve glycemic control in adults with type 2 diabetes mellitus. **Glimepiride** is a sulfonylurea that stimulates insulin release from pancreatic beta cells by binding to the sulfonylurea receptor on the ATP-sensitive potassium channel, while **pioglitazone** is a thiazolidinedione (TZD) that acts as a potent agonist of the peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in muscle, adipose tissue, and the liver. The combination provides complementary mechanisms: glimepiride increases insulin secretion, whereas pioglitazone reduces insulin resistance. The product is approved as adjunct therapy to diet and exercise for glycemic control in adults with type 2 diabetes, particularly when treatment with both agents is considered appropriate. It is not indicated for type 1 diabetes or diabetic ketoacidosis[1][2][3][4].

Brand names

Duetact

Other names

pioglitazone and glimepiride